Cart
sales@molnova.com
Secukinumab B
CAS No. 1229022-83-6
Secukinumab B( —— )
Catalog No. M37701 CAS No. 1229022-83-6
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 487 | In Stock |
|
| 10MG | 675 | In Stock |
|
| 25MG | 1036 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSecukinumab B
-
NoteResearch use only, not for human use.
-
Brief DescriptionSecukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
-
DescriptionAnti-Human IL-17A is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1229022-83-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Reich K, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017 Mar;176(3):752-758. ?
molnova catalog
related products
-
Apilimod 2HCl
Apilimod 2HCl (STA 5326 2HCl) is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation, IL-1β secretion, and cellular pyroptosis, and is used in the study of amyotrophic lateral sclerosis.
-
Resiniferatoxin
Resiniferatoxin inhibits the production of Th1 cytokines, contributing to the defense against T. spiralis infection, and can be used in studies about the modulator of the immune response.
-
Nodosin
Nodosin has an anti-inflammatory function via inhibition of IL-2. Nodosin perfusion provides a potential protective effect by inducing HO-1 expression to attenuate ischemia/reperfusion injury in liver transplantation.
